HK1210053A1 - Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition - Google Patents

Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition

Info

Publication number
HK1210053A1
HK1210053A1 HK15111028.6A HK15111028A HK1210053A1 HK 1210053 A1 HK1210053 A1 HK 1210053A1 HK 15111028 A HK15111028 A HK 15111028A HK 1210053 A1 HK1210053 A1 HK 1210053A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
release pharmaceutical
oral sustained
hydromorphone hydrochloride
containing oral
Prior art date
Application number
HK15111028.6A
Other languages
English (en)
Chinese (zh)
Inventor
Shuichi Yada
Hideki Yano
Kazuhiro Yoshida
Sachiko Fukui
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1210053A1 publication Critical patent/HK1210053A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
HK15111028.6A 2012-09-03 2015-11-09 Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition HK1210053A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012192783 2012-09-03
PCT/JP2013/073519 WO2014034929A1 (ja) 2012-09-03 2013-09-02 ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物

Publications (1)

Publication Number Publication Date
HK1210053A1 true HK1210053A1 (en) 2016-04-15

Family

ID=50183727

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111028.6A HK1210053A1 (en) 2012-09-03 2015-11-09 Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition

Country Status (12)

Country Link
US (1) US9827199B2 (xx)
EP (1) EP2893928B1 (xx)
JP (1) JP6129184B2 (xx)
KR (1) KR102127625B1 (xx)
CN (1) CN104768552A (xx)
BR (1) BR112015004190A2 (xx)
CA (1) CA2883077C (xx)
ES (1) ES2706994T3 (xx)
HK (1) HK1210053A1 (xx)
RU (1) RU2665372C2 (xx)
TW (1) TWI566786B (xx)
WO (1) WO2014034929A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540318B1 (en) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
JP7365157B2 (ja) * 2018-07-17 2023-10-19 沢井製薬株式会社 イミダフェナシン含有錠剤の製造方法
KR20240121528A (ko) * 2023-02-02 2024-08-09 피투케이바이오 주식회사 산화티탄을 사용하지 않는 안전한 필름코팅용 조성물 및 이를 코팅한 식품 및 의약품의 제제

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547943A (en) 1986-04-30 1996-08-20 Chugai Seiyaku Kabushiki Kaisha Sucralfate preparation
DE3714159C2 (de) 1986-04-30 1996-09-19 Chugai Pharmaceutical Co Ltd Sucralfat-Zubereitung
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
KR20010012402A (ko) 1997-05-09 2001-02-15 세이지 파마슈티칼스, 인크. 안정한 약제학적 경구 투여형
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
CA2309542A1 (en) 1997-11-12 1999-05-20 Boehringer Mannheim Pharmaceuticals Corp. - Smithkline Beecham Corporati On Limited Partnership No.1 Novel oral dosage form for carvedilol
US20020054911A1 (en) 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
ES2199857T3 (es) 1999-08-26 2004-03-01 Neurocrine Biosciences, Inc. Composiciones sedantes-hipnoticas de liberacion controlada y metodos relacionados con ellas.
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
JP4641696B2 (ja) 1999-09-30 2011-03-02 大塚製薬株式会社 消化管下部溶解性コーティング製剤
JP2001270821A (ja) 2000-03-23 2001-10-02 Eisai Co Ltd 服用感が優れた散剤
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
IN191028B (xx) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
CA2451605C (en) 2001-06-20 2010-08-10 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
PL368402A1 (en) 2001-08-09 2005-03-21 Daiichi Pharmaceutical Co, Ltd. Diamine derivatives
JP4644397B2 (ja) 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
HRP20020124A2 (en) 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
JP2004026750A (ja) 2002-06-27 2004-01-29 Nippon Shinyaku Co Ltd 薬物の安定化法
WO2004024184A1 (ja) 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
US20040052844A1 (en) 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
AU2003275953A1 (en) 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
PL377550A1 (pl) 2002-12-25 2006-02-06 Daiichi Pharmaceutical Co., Ltd. Pochodne diamin
CN101219115B (zh) 2003-06-27 2012-09-19 大塚制药株式会社 药物持续释放颗粒及其制备方法
WO2005048979A2 (en) 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
WO2005051325A2 (en) 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20060008418A1 (en) 2004-07-12 2006-01-12 Solidtech Animal Health, Inc. Packaging and method for solid dose administration of an electronic identification chip and medicaments
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US20060280789A1 (en) 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060159753A1 (en) 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
RS20070511A (xx) 2005-06-29 2009-01-22 Panacea Biotec Ltd., Farmaceutske kompozicije sa modifikovanim otpuštanjem i postupci za njihovo dobijanje
CA2620370A1 (en) 2005-08-30 2007-03-22 Nicholas Piramal India Limited Extended release pharmaceutical composition of metformin and a process for producing it
CA2621640C (en) 2005-09-16 2013-10-29 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing the same
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8652529B2 (en) * 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
JP2009532462A (ja) 2006-04-05 2009-09-10 カディラ・ヘルスケア・リミテッド 調節放出クロピドグレル製剤
MX2008013675A (es) 2006-04-26 2009-03-06 Supernus Pharmaceuticals Inc Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal.
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
EP2067475A4 (en) 2006-09-26 2010-12-15 Astellas Pharma Inc PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
CN100563637C (zh) 2006-10-13 2009-12-02 北京红林制药有限公司 一种控释给药的药芯组合物和控释制剂及其制备方法
JP2008169173A (ja) 2007-01-15 2008-07-24 Kissei Pharmaceut Co Ltd 炭水化物分解酵素阻害剤の胃内滞留型徐放性製剤
EP2105133A1 (en) 2007-01-15 2009-09-30 Kissei Pharmaceutical Co., Ltd. Intragastric floating-type levodopa sustained-release preparation
KR20080076382A (ko) 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
BRPI0809205B8 (pt) 2007-03-29 2021-05-25 Daiichi Sankyo Co Ltd composição farmacêutica
WO2009047802A2 (en) 2007-10-10 2009-04-16 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
JP2011502140A (ja) 2007-10-29 2011-01-20 ルピン・リミテッド トルテロジンの制御放出型医薬組成物
PT2057984E (pt) * 2007-11-09 2010-03-10 Acino Pharma Ag Comprimidos retard com hidromorfona
RU2010129907A (ru) * 2007-12-17 2012-01-27 Лабофарм Инк. (CA) Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление
SI22849A (sl) 2008-08-01 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Ropinirolni pripravek
FR2951378B1 (fr) 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
CA2784407A1 (en) * 2009-12-17 2011-07-14 Cima Labs Inc. Abuse-resistant formulations
WO2011102505A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
EP2540318B1 (en) * 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
TW201200165A (en) 2010-02-22 2012-01-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
MX347753B (es) * 2010-02-24 2017-05-10 Cima Labs Inc Formulaciones resistentes al abuso.
SE1251371A1 (sv) * 2010-05-10 2012-12-27 Euro Celtique Sa Farmaceutiska kompositioner innefattande hydromorfon och naloxon

Also Published As

Publication number Publication date
BR112015004190A2 (pt) 2017-07-04
EP2893928A4 (en) 2016-04-27
CA2883077C (en) 2017-03-07
JPWO2014034929A1 (ja) 2016-08-08
EP2893928A1 (en) 2015-07-15
KR20150045446A (ko) 2015-04-28
TW201414509A (zh) 2014-04-16
US9827199B2 (en) 2017-11-28
RU2665372C2 (ru) 2018-08-29
ES2706994T3 (es) 2019-04-02
TWI566786B (zh) 2017-01-21
RU2015112122A (ru) 2016-10-20
WO2014034929A1 (ja) 2014-03-06
EP2893928B1 (en) 2018-10-24
KR102127625B1 (ko) 2020-06-29
JP6129184B2 (ja) 2017-05-17
CA2883077A1 (en) 2014-03-06
US20150231083A1 (en) 2015-08-20
CN104768552A (zh) 2015-07-08

Similar Documents

Publication Publication Date Title
ZA201703992B (en) Inhalable pharmaceutical compositions
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
IL246377A0 (en) Pharmaceutical preparations for oral administration
ZA201501930B (en) Pharmaceutical composition
HK1199821A1 (en) Oral pharmaceutical composition
HRP20181193T1 (hr) Farmaceutska kompozicija koja se može oralno administrirati
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
AP2015008208A0 (en) Pharmaceutical administration forms comprising
HK1210053A1 (en) Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
EP2709593A4 (en) PHARMACEUTICAL COMPOSITION OF MULTIPLE PARTICLES
ZA201502987B (en) Pharmaceutical composition
EP2868319A4 (en) ORAL PHARMACEUTICAL PREPARATION OF ARIPIPRAZOLE
EP2851074A4 (en) ANALGETIC PHARMACEUTICAL COMPOSITION
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
EP2628488A4 (en) PHARMACEUTICAL COMPOSITION WITH MAINTAINED RELEASE
GB201301179D0 (en) Pharmaceutical composition comprising opioid analgesic
ZA201400751B (en) Pharmaceutical composition
HUE043019T2 (hu) Gyógyszerészeti készítmények kombinációs terápia céljára

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230904